Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 412

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 412
---
 ARE STRONGLY URGED TO CONSULT
THEIR TAX ADVISORS REGARDING THE U.S. FEDERAL, STATE, LOCAL AND FOREIGN TAX CONSEQUENCES OF THE DOMESTICATION AND ITS APPLICATION
TO THEM.

<div align='center'>236

EXPENSES OF THIS OFFERING</div>

Set forth below is an itemization
of our total expenses, which are expected to be incurred in connection with the offer and sale of the Class A Ordinary Shares by us. With
the exception of the SEC registration fee, all amounts are estimates.

| Securities and Exchange Commission registration fee | $ | 573.12 |
| Legal fees and expenses                             | $ |        |
| Other professional fees                             | $ |        |
| Placement agent’s fee                               | $ |        |
| Total                                               | $ |        |

<div align='center'>LEGAL MATTERS</div>

The validity of the Class
A Ordinary Shares being offered by this prospectus and other legal matters relating to Cayman Islands law will be passed upon for the
Company by Campbells. Certain legal matters with respect to the United States federal securities law and New York law will be passed upon
for the Company by Hunter Taubman Fischer & Li LLC, New York, New York.

<div align='center'>EXPERTS</div>

The consolidated balance sheets
of Aptorum Group Limited as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, changes
in equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes, incorporated by referenced
in this prospectus have been so included in reliance on the report (which contains an explanatory paragraph relating to the Company’s
ability to continue as a going concern as described in Note 2 to the financial statements) of Marcum Asia CPAs LLP, an
independent registered public accounting firm given on the authority of such firm as experts in accounting and auditing.

The consolidated balance sheet
of DiamiR Biosciences Corp. as of May 31, 2025, and the related consolidated statements of operations, changes in stockholders’
deficit and cash flows for the year ended May 31, 2025, included herein, have been audited by CBIZ CPAs P.C., independent registered
public accounting firm, as set forth in their report appearing elsewhere herein, which contains an explanatory paragraph relating to substantial
doubt about the